# Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease

> **NCT00005969** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Chemotherapy
- **DRUG:** Tretinoin Liposome

## Key facts

- **NCT ID:** NCT00005969
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 1999-09
- **Primary completion:** 2001-01
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn.
- **Last updated:** 2012-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005969, "Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00005969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*